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Objective: To evaluate the efﬁ  cacy of a combined calcium and vitamin D (Ca-D3) supplement 
for vitamin D deﬁ  ciency in a small group of postmenopausal women.
Methods: A prospective open label 3 month-study.
Participants: 23 postmenopausal women (mean age 61.2 yrs) with vitamin D deﬁ  ciency were 
given a combined oral Ca-D3 supplement called “Osteoblast”. The supplement comprises 500 mg 
elemental calcium and 500 IU of cholecalciferol. The dosing regimen comprised a loading dose 
of 1000 IU of cholecalciferol per day for one month (two tablets) and thereafter a maintenance 
dose of 500 IU of cholecalciferol per day for 2 months (one tablet).
Outcome measure: Serum was collected for calcium, 25 hydroxyvitamin D3 (25OHD3), 
and PTH measurements, as well as early morning 2-hour urine calcium/creatinine excretion 
index (Uca/creat). Specimens were collected at baseline and after 3 months of therapy. Data 
are reported as mean ± 1 standard error and 95% conﬁ  dence intervals.
Results: Data was available for the 21 subjects who completed the study. Two subjects (9%) 
withdrew because of gastrointestinal intolerance. There were 3 subjects with moderate (12.5–24 
nmol/L) and 18 with mild (25–49 nmol/L) vitamin D deﬁ  ciency. Ten subjects (48%) had sec-
ondary hyperparathyroidism. Following the oral Ca-D3 combination, serum 25OHD3 levels 
normalised in all subjects with 18 (86%) subjects achieving values of greater than 70 nmol/L. 
Serum 25OHD3 levels increased from 36 (31–41) to 91 (79–102) nmol/L (p = 0.0001), increas-
ing by an average of 152% over the 3-month period. There was a corresponding 38% decrease 
in serum PTH concentrations at 3 months (5.1 + 0.6 pmol/L), compared with baseline (8.0 + 1 
pmol/L) (p = 0.001). No subject developed hypercalcemia, but an elevated Uca/creat excretion 
index occurred in one subjects.
Conclusions: A combined oral Ca-D3 product (Osteoblast) is effective for treating vitamin D 
deﬁ  ciency and is adequately tolerated.
Introduction
There is a resurgence of vitamin D deﬁ  ciency in the developed world, even in “sunny” 
Australia (Diamond et al 2005). The clinical spectrum ranges from mild to severe 
deﬁ  ciency, with serum 25-hydroxyvitamin D (25OHD) levels less than 25 nmol/L. 
The prevalence of vitamin D deﬁ  ciency among elderly people living in residential 
homes has been estimated to be at least 50% (Flicker et al 2003). Other high risk 
groups include ethnic populations from the Horn of Africa, India, and Pakistan, and 
patients with gastrointestinal malabsorption syndromes (Skull et al 2003; Diamond 
et al 2005). Vitamin D deﬁ  ciency is frequently seen in women treated for osteoporosis 
(MORE study) (Ettinger et al 1999).
Vitamin D deﬁ  ciency leads to hypocalcemia, secondary hyperparathyroidism, 
and increased bone turnover (Adams et al 1999; Leboff et al 1999). This may be 
associated with osteoporosis and osteofragility fractures, which occur due to reduction Clinical Interventions in Aging 2008:3(1) 184
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in bone strength superimposed on trauma such as a fall. A 
deﬁ  ciency in skeletal and total body calcium is frequently part 
of the vitamin D deﬁ  ciency syndrome. Calcium deﬁ  ciency is 
insidious in its early stages and potentially irreversible in the 
latter, making preventative optimization the only successful 
pathway in all patients perceived to be at risk of calcium 
deﬁ  ciency (Arthur 2007).
Calcium and vitamin D repletion can improve bone min-
eral density and reduce fracture risk in individuals with frank 
vitamin D deﬁ  ciency. Moreover, calcium and vitamin D supple-
mentation is often required as a necessary adjunct to all forms of 
anti-osteoporotic therapies. The current calcium requirements are 
1–1.3 g/day for adults (Bryant et al 1999). The need for vitamin D 
supplementation is dependent on the serum 25 hydroxyvitamin D 
level, with values of greater than 60–70 nmol/L (Peacock et al 
1985) considered for optimal bone health.
A number of “over the counter” calcium and vitamin D 
preparations are currently available for both the treatment 
and prevention of osteoporosis and vitamin D deﬁ  ciency. The 
main Ca-D3 combination supplement currently available in 
Australia is Caltrate D which contains 200 IU of vitamin D3 
combined with 600 mg elemental calcium. Most other supple-
ments contain either D3 or calcium in a single preparation. 
We therefore undertook an open-labelled prospective study 
assessing the role of “Osteoblast”, a combined oral calcium 
carbonate (500 mg) and cholecalciferol (500 IU) tablet as 
therapy for mild to moderate vitamin D deﬁ  ciency (for full 
list of ingredients, and comparison with other products avail-
able on the market, please see Table 1).
Method
We conducted a prospective open-label 3 month study on 
23 women (mean age 61.2 years) with vitamin D deﬁ  ciency. 
These women were given a combined oral Ca-D3 supplement 
called “Osteoblast”. This preparation contains 500 IU chole-
calciferol and 500 mg elemental calcium as a carbonate salt. 
This combined high dose vitamin D supplement appeared 
ideal, not only for calcium supplementation but in addition, 
as therapy for vitamin D deﬁ  ciency.
Consecutive women with postmenopausal osteoporosis 
who displayed biochemical evidence of vitamin D deﬁ  ciency 
(serum 25-hydroxyvitamin D3 50 nmol/L) presenting 
to the metabolic bone clinic at St George Hospital were 
recruited if they had no evidence of hypercalcemia (serum 
calcium 2.65mmol/L), primary hyperparathyroidism, 
thyrotoxicosis, Paget’s disease, malignancy, signiﬁ  cant renal 
impairment (serum creatinine 0.15 mmol/l), or were cur-
rently receiving treatment with calcitriol or high-dose oral 
calcium supplements (1200 mg/day of elemental calcium). 
All gave informed consent and were administered 2 tablets 
of osteoblast daily (morning or evening) for one month 
and thereafter one tablet daily for 2 months. The study was 
conducted during winter. Whilst a diary estimating sunlight 
exposure was not requested, patients were advised not to 
change their sun exposure pattern. A strict dietary calcium 
recall was not undertaken. Patients were advised not to add 
any vitamin supplements to their diet or to adjust their dietary 
calcium intake during the study.
Participants were evaluated by biochemical assessments 
at baseline and after 3 months of therapy. Since this was a 
pilot study, the trial was not registered. However, the study 
was performed according to National Health and Medical 
Research Council guidelines.
Serum (fasting) and urinary (2-hour) calcium, urea 
and creatinine levels were determined by autoanalyser 
methods. Hypercalcemia was deﬁ  ned as a serum calcium 
Table 1 “Over the counter” calcium and vitamin D preparations available
  Caltrate  Swisse   Blackmores   Nature’s own  NutraLife super  Blooms  RDIs and Als
  plus  calverv   bio calcium  calcium and  calcium  osteo
   M3    magnesium  complete  blast
        with vitamin D3 
Calcium  600 mg  305 mg  350 mg  250 mg  270 mg  500  1000–1300 mg
Vitamin D3  200 iu  480 iu  100 iu  200 iu  100 iu  500 iu  200–600 iu
Magnesium  50 mg  300 mg    50 mg  250 mg  110 mg  310–420 mg
Manganese  1.8 mg  2.5 mg      1. mg  2.5 mg  5–55 mg
Zinc  7.5 mg  12.15 mg      0.5 mg  5 mg  8–14 mg
Copper  1 mg  35 mcg        1 mg  1.2–1/7 mg
Vitamin K          2.2 mcg  23 mcg  60–70 mcg
Betacarotene            300 mcg  700–1100 mcg
(as Retinol equivalents)             
Boron          0.4 mg  1 mg  -
Silicon           7  mg  -Clinical Interventions in Aging 2008:3(1) 185
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concentration higher than 2.65 mmol/L. Two-hour urine 
calcium/creatinine excretion indices were used to determine 
hypercalciuria. A urine calcium/creatinine excretion index 
over 0.60 was considered abnormal.
All serum 25OHD3 specimens were measured using the 
LIAISON 25 OH Vitamin D TOTAL assay (DiaSorin Inc, 
Stillwater, USA). Speciﬁ  city for 25OHD3 was 100%, and 
intra-assay precision was 5.3% at 26.5 nmol/L and 6.1% at 
151 nmol/L.
Serum levels of intact parathyroid hormone (PTH) 
were measured by chemiluminometric technology (Advia 
Centaur Assay, Bayer Corp, USA). The intra-assay preci-
sion was 5.2% at 4.3 pmol/L and 3.4% at 23.7 pmol/L. 
Hyperparathyroidism was deﬁ  ned as a serum PTH level 
over 7.5 pmol/L.
Statistical analysis
Data are presented as mean ± 1 standard error and 95% con-
ﬁ  dence intervals. Group mean values were compared by stu-
dent t-test. Signiﬁ  cance was considered if p-value  0.05.
Results
Data was available for the 21 subjects who completed the 
study (Table 2). Two subjects (9%) withdrew because of gas-
trointestinal intolerance. There were 3 subjects with moderate 
(12.5–24 nmol/L) and 18 with mild (25–49 nmol/L) vitamin 
D deﬁ  ciency. Ten subjects (48%) had secondary hyperpara-
thyroidism. Following the oral Ca-D3 combination, serum 
25OHD3 levels normalized in all subjects with 18 (86%) 
subjects achieving values of greater than 70 nmol/L. Serum 
25OHD3 levels increased from 36 (31–41) to 91 (79–102) 
nmol/L (p = 0.0001), increasing by an average of 152% over 
the 3-month period. There was a corresponding 38% decrease 
in serum PTH concentrations at 3 months (5.1 + 0.6 pmol/L), 
compared with baseline (8.0 + 1 pmol/L) (p = 0.001). No 
subject developed hypercalcemia, but an elevated Uca/creat 
excretion index occurred in one subject.
Discussion
The major source of vitamin D in humans is sunlight. In the 
absence of adequate sunlight exposure, supplementation 
becomes important. Data suggests that serum 25OHD3 of 
at least 60–70 nmol/L or greater is required for optimum 
bone health and is protective against secondary hyperpara-
thyroidism and decreased bone density (Peacock et al 1985). 
In Australia, the National Health and Medical Research 
Council recommends a daily oral intake of at least 400 IU 
vitamin D for those who are at risk of vitamin D deﬁ  ciency 
(NHMRC 1991).
Vitamin D repletion in individuals presenting with vita-
min D deﬁ  ciency has been shown to have a positive effect on 
bone biology, resulting in mineralization of osteoid, increases 
in bone mineral density measurements and reduced fracture 
rates (Diamond et al 2005). In a landmark trial in elderly 
institutionalized women, 800 IU of oral vitamin D3 with 
calcium supplements resulted in signiﬁ  cant reduction in both 
nonvertebral (3.8%) and hip (2%) fractures, and a signiﬁ  cant 
improvement in femoral neck bone density after 36 months of 
therapy (Chapuy et al 1992). A report of bone histomorpho-
metric changes in 28 patients with osteomalacia treated with 
various vitamin D preparations and calcium showed an 80% 
reduction in osteoid volume and an increase in mineralized 
bone volume in cortical (+7.5%) and trabecular bone (+40%) 
after therapy (Parﬁ  tt et al 1985).
Calcium deﬁ  ciency can be secondary to vitamin D deﬁ  -
ciency. Vitamin D facilitates calcium absorption through 
the small intestine. In addition to vitamin D deﬁ  ciency 
being common, a Melbourne study of 1045 women aged 
20–92 years in 2000 revealed that approximately 76% con-
sumed less than the RDI for calcium and an additional 14% 
Table 2 Study results 
Variable  Mean  SEM  95% CI   p-value
     range
Age (years)  61.2   3.2   27–86 
(S) Caa (mmol/L)  2.29  0.02  2.24–2.34 
(S) Cab (mmol/L)  2.34  0.02  2.29–2.39  p = 0.05 vs basal
(S) PTHa (pmol/L)  8.0  1.0  5.8–10.2 
(S) PTHb (pmol/L)  5.1  0.6  3.8–6.3  p = 0.006 vs basal
(S) 25OHD3a (nmol/L)  36.1  2.2  31–41 
(S) 25OHD3b (nmol/L)  90.6  5.6  79–102  p = 0.0001 vs basal
U Ca/Creat (Mmol/Mmol)  0.28  0.06  0.17–0.39 
Abbreviations: a, before; b, after.Clinical Interventions in Aging 2008:3(1) 186
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demonstrated a grossly inadequate intake of 300 mg/day 
(Arthur 2007). These ﬁ  gures appear consistent with the ﬁ  nd-
ings of the 1995 National Nutrition Survey and larger US 
studies. Calcium supplementation is effective in preventing 
further deterioration in bone quality and reducing fracture 
rates. It cannot, however, reverse the condition.
The accepted paradigm for effective treatment of vita-
min D deﬁ  ciency is correction of the vitamin D deﬁ  ciency 
with vitamin D supplements together with calcium. These 
are taken together with anti-osteoporosis medications when 
indicated.
In Australia a number of combined Ca-D3 preps are avail-
able over the counter. Table 1 compares some of the main 
products currently available in the marketplace.
Our study assessed the role of “Osteoblast”, a combina-
tion oral tablet with 500 mg calcium and 500 IU cholecalcif-
erol, as therapy for mild to moderate vitamin D deﬁ  ciency. 
Our results showed a signiﬁ  cant improvement in vitamin D 
status accompanied by a signiﬁ  cant decrease in PTH levels, 
proving efﬁ  cacy in the treatment of this condition. Data by 
Vieth and colleagues (2004) has shown that supplementation 
with cholecalciferol 600 IU daily for 2–6 months increased 
serum 25 hydroxyvitamin D levels from 49 to 79 nmol/L. 
These data are similar to our ﬁ  ndings. Based on our results, 
we are recommending adequate Ca-D3 for bone health as part 
of therapy for postmenopausal osteoporosis, not as therapy 
for severe vitamin D deﬁ  ciency.
Conclusion
A combined oral Ca-D3 product is effective for treating 
vitamin D deﬁ  ciency and is adequately tolerated.
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